

Dacarbazine

Catalog No: tcsc1772



Available Sizes

Size: 200mg

Size: 1g



Specifications

CAS No:

4342-03-4

Formula:

$C_6H_{10}N_6O$

Pathway:

Cell Cycle/DNA Damage

Target:

Nucleoside Antimetabolite/Analog

Purity / Grade:

>98%

Solubility:

DMSO : 6.42 mg/mL (35.24 mM; Need ultrasonic and warming); H₂O :

Alternative Names:

Imidazole Carboxamide

Observed Molecular Weight:

182.18


Product Description

Dacarbazine(DTIC-Dome; DTIC) is an antineoplastic agent. It has significant activity against melanomas.

Target: Nucleoside antimetabolite/analog

Approved: May 1975

Dacarbazine (DTIC) is the only single-agent approved by the Food and Drug Administration for treating metastatic melanoma. With DTIC as single agent, an approximately 20% objective response rate can be achieved with median response duration of 5 to 6 months and complete response rates of 5% [1]. Dacarbazine (DTIC) has activity in advanced previously untreated pancreatic islet cell tumors [2]. In the intent-to-treat population, median survival time was 7.7 months for patients treated with temozolomide and 6.4 months for those treated with DTIC (hazards ratio, 1.18; 95% confidence interval [CI], 0.92 to 1.52). Median PFS time was significantly longer in the temozolomide-treated group (1.9 months) than in the DTIC-treated group (1.5 months) (P = .012; hazards ratio, 1.37; 95% CI, 1.07 to 1.75) [3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!